[Anti-streptokinase antibodies]

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Thrombolytic therapy improves acute myocardial infarction (AMI) management but has limitations like incomplete patency, reocclusion, and bleeding risks.
• Streptokinase (SK) is an inexpensive thrombolytic but can elicit an immune response, producing anti-streptokinase (anti-SK) antibodies.
• These anti-SK antibodies, from prior streptococcal infections or SK administration, can cause allergic reactions or neutralize SK, reducing its efficacy.

Purpose of the Study:

• To investigate the prevalence and effects of anti-SK antibodies in patients undergoing thrombolysis for AMI.
• To explore the potential in vitro platelet aggregant effect of anti-SK antibodies in the presence of SK.
• To assess the impact of anti-SK antibodies on the efficacy and safety of SK thrombolysis.

Main Methods:

• Review of existing literature on thrombolysis, SK, and anti-SK antibodies.
• Analysis of clinical trial data (where available) concerning anti-SK antibody presence and thrombolysis outcomes.
• In vitro studies examining the interaction between anti-SK antibodies, SK, and platelets.

Main Results:

• The prevalence of anti-SK antibodies in the general population and AMI patients is not well-established.
• Anti-SK antibodies are known to have an anti-lytic effect, reducing SK effectiveness.
• A potential platelet aggregant effect of anti-SK antibodies in the presence of SK was not adequately considered in previous trials.

Conclusions:

• Anti-SK antibodies pose a significant challenge to the repeated use of SK for thrombolysis due to potential allergic reactions and neutralization.
• The influence of pre-existing anti-SK antibodies, including their platelet aggregant effects, on thrombolysis outcomes warrants further investigation.
• Current evidence suggests caution and contraindicates readministration of SK in patients previously treated with SK-containing products.